Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be 20 years of age or older~2. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes. (OAG in one eye and OHT in the fellow eye is acceptable)~3. BCVA 0.1 or better in decimal unit using Landolt-C chart or its equivalent~4. Able and willing to give signed informed consent and following study instructions~Exclusion Criteria:~1. Clinically significant ocular diseases~2. Pseudoexfoliation or pigment dispersion component glaucoma, history of narrow angle closure glaucoma or narrow angles~3. Previous glaucoma intraocular surgery~4. Refractive surgery in either eye~5. Ocular trauma~6. Ocular infection or inflammation~7. Known hypersensitivity to benzalkonium chloride or excipient of netarsudil ophthalmic solution~8. Cannot demonstrate proper delivery of the eye drop~9. Clinically significant abnormalities in screen lab tests~10. Clinically significant systemic disease~11. Participation in any investigational study within 30 days of screening~12. Women of child-bearing potential who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil Ophthalmic Solution 0.01% (Type: EXPERIMENTAL): 1 drop daily into each eye in the evening for 28 days
- Netarsudil Ophthalmic Solution 0.02% (Type: EXPERIMENTAL): 1 drop daily into each eye in the evening for 28 days
- Netarsudil Ophthalmic Solution 0.04% (Type: EXPERIMENTAL): 1 drop daily into each eye in the evening for 28 days
- Netarsudil Ophthalmic Solution Placebo (Type: PLACEBO_COMPARATOR): 1 drop daily into each eye in the evening for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).